Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AGLTS:0VRQ -0.42%36 Debt-to-EBITDA is -1.56 as of Mar. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 36/100 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 295 Biotechnology companies, CRISPR Therapeutics AG ranks worse than 338982.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CRISPR Therapeutics AG's Debt-to-EBITDA or its related term are showing as below:
LTS:0VRQ'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.26 Med: -0.32 Max: 1.02
Current: -1.26
During the past 12 years, the highest Debt-to-EBITDA Ratio of CRISPR Therapeutics AG was 1.02. The lowest was -1.26. And the median was -0.32.
LTS:0VRQ's Debt-to-EBITDA is ranked worse than 100% of 295
companies
in the Biotechnology industry
Industry Median: 1.14
vs LTS:0VRQ: -1.26
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CRISPR Therapeutics AG Debt-to-EBITDA Related Terms
CRISPR Therapeutics AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs MANE, EWTX, CAI: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
CRISPR Therapeutics AG (LTS:0VRQ) has a Debt-to-EBITDA of -1.56 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CRISPR Therapeutics AG. According to the industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 295 companies in the Biotechnology industry.
Is CRISPR Therapeutics AG's Debt-to-EBITDA too high?
CRISPR Therapeutics AG's current Debt-to-EBITDA is -1.56. Based on the distribution chart, CRISPR Therapeutics AG ranks #999999 out of 295 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Debt-to-EBITDA compare to MANE and EWTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 295 companies for Debt-to-EBITDA. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 295 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CRISPR Therapeutics AG. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Debt-to-EBITDA is -1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The current Debt-to-EBITDA is -1.56. CRISPR Therapeutics AG's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Debt-to-EBITDA is -1.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
36GF Score
Get the complete analysis for LTS:0VRQ
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
